Collegium Pharmaceutical Inc (COLL)vsZoetis Inc (ZTS)
COLL
Collegium Pharmaceutical Inc
$24.95
+0.56%
HEALTHCARE · Cap: $770.98M
ZTS
Zoetis Inc
$82.96
+0.47%
HEALTHCARE · Cap: $33.45B
Smart Verdict
WallStSmart Research — data-driven comparison
Zoetis Inc generates 1065% more annual revenue ($9.49B vs $815.19M). ZTS leads profitability with a 26.4% profit margin vs 4.7%. COLL appears more attractively valued with a PEG of 0.72. COLL earns a higher WallStSmart Score of 58/100 (C).
COLL
Buy58
out of 100
Grade: C
ZTS
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+88.3%
Fair Value
$384.11
Current Price
$24.95
$359.16 discount
Margin of Safety
+11.2%
Fair Value
$144.94
Current Price
$82.96
$61.98 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 22.9%
Every $100 of equity generates 75 in profit
Strong operational efficiency at 38.2%
Safe zone — low bankruptcy risk
Keeps 26 of every $100 in revenue as profit
Attractively priced relative to earnings
Areas to Watch
3.3% revenue growth
Smaller company, higher risk/reward
4.7% margin — thin
Earnings declined 29.0%
Trading at 10.2x book value
Expensive relative to growth rate
Revenue declined 1.3%
Earnings declined 11.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : COLL
The strongest argument for COLL centers on PEG Ratio, Price/Book, Operating Margin. PEG of 0.72 suggests the stock is reasonably priced for its growth.
Bull Case : ZTS
The strongest argument for ZTS centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 26.4% and operating margin at 38.2%.
Bear Case : COLL
The primary concerns for COLL are Revenue Growth, Market Cap, Profit Margin. Debt-to-equity of 2.75 is elevated, increasing financial risk. Thin 4.7% margins leave little buffer for downturns.
Bear Case : ZTS
The primary concerns for ZTS are Price/Book, PEG Ratio, Revenue Growth. Debt-to-equity of 2.80 is elevated, increasing financial risk.
Key Dynamics to Monitor
COLL profiles as a value stock while ZTS is a declining play — different risk/reward profiles.
COLL carries more volatility with a beta of 0.73 — expect wider price swings.
COLL is growing revenue faster at 3.3% — sustainability is the question.
ZTS generates stronger free cash flow (717M), providing more financial flexibility.
Bottom Line
COLL scores higher overall (58/100 vs 56/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Collegium Pharmaceutical Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and markets pain management medications. The company is headquartered in Stoughton, Massachusetts.
Zoetis Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?